Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
43
SMTI Quote, Financials, Valuation and Earnings
Last price:
$35.00
Seasonality move
:
44.69%
Day range:
$31.82 - $35.08
52-week range:
$26.00 - $43.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.69x
P/B ratio:
7.49x
Volume:
32.3K
Avg. volume:
35.7K
1-year change:
-10.87%
Market cap:
$298.2M
Revenue:
$65M
EPS (TTM):
-$0.99
Analysts' Opinion
-
Consensus RatingSanara MedTech has received a consensus rating of . The company's average rating is a based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $44.00, Sanara MedTech has an estimated upside of 28.99% from its current price of $34.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $44.00 representing 100% downside risk from its current price of $34.11.
Fair Value
-
According to the consensus of 0 analysts, Sanara MedTech has 28.99% upside to fair value with a price target of $44.00 per share.
SMTI vs. S&P 500
-
Over the past 5 trading days, Sanara MedTech has underperformed the S&P 500 by -0.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sanara MedTech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sanara MedTech has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Sanara MedTech reported revenues of $21.7M.
Earnings Growth
-
Sanara MedTech earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sanara MedTech reported earnings per share of -$0.34.
Enterprise value:
311.6M
EV / Invested capital:
4.48x
Price / LTM sales:
3.69x
EV / EBIT:
--
EV / Revenue:
3.99x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-156.42x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$70.4M
Return On Assets:
-10.94%
Net Income Margin (TTM):
-10.71%
Return On Equity:
-19.67%
Return On Invested Capital:
-14.62%
Operating Margin:
-8.2%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $37.6M | $62.6M | $78.1M | $16M | $21.7M | |
| Gross Profit | $32.8M | $54.2M | $70.4M | $14.3M | $19.7M | |
| Operating Income | -$12.6M | -$8.5M | -$8.5M | -$1.6M | -$1.8M | |
| EBITDA | -$11.6M | -$4.8M | -$1.9M | $91K | -$851.6K | |
| Diluted EPS | -$0.98 | -$1.00 | -$0.99 | -$0.13 | -$0.34 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.3M | $27.2M | $20.6M | $19.4M | $31.9M | |
| Total Assets | $9.7M | $37.9M | $61.5M | $75.5M | $88.5M | |
| Current Liabilities | $3.1M | $4.2M | $9.2M | $13.2M | $14.3M | |
| Total Liabilities | $4.1M | $4.5M | $16.8M | $31.4M | $49.1M | |
| Total Equity | $5.6M | $33.4M | $44.6M | $44.1M | $39.5M | |
| Total Debt | $583K | -- | -- | $9.7M | $30.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.7M | -$3M | -$1.8M | $1.1M | $2.1M | |
| Cash From Investing | -$4.6M | -$10.5M | -$6.5M | -$10.1M | -$6.4M | |
| Cash From Financing | -$765.5K | $9.5M | $18.4M | $9.2M | $14.4M | |
| Free Cash Flow | -$7.5M | -$3.3M | -$2M | $893.8K | $2M | |
SMTI
Sector
Market Cap
$298.2M
$45.6M
Price % of 52-Week High
78.86%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-2.2%
-0.74%
1-Year Price Total Return
-10.87%
-31.35%
Beta (5-Year)
1.574
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$33.68
200-day SMA
Buy
Level
$32.49
Bollinger Bands (100)
Buy
Level
30.51 - 35.75
Chaikin Money Flow
Buy
Level
10.7M
20-day SMA
Sell
Level
$35.30
Relative Strength Index (RSI14)
Sell
Level
46.99
ADX Line
Buy
Level
16.39
Williams %R
Neutral
Level
-53.2182
50-day SMA
Sell
Level
$34.57
MACD (12, 26)
Sell
Level
-0.52
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
9.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.4441)
Buy
CA Score
(Annual)
Level (0.302)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (1.7013)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Stock Forecast FAQ
In the current month, SMTI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SMTI average analyst price target in the past 3 months is $44.00.
-
Where Will Sanara MedTech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sanara MedTech share price will rise to $44.00 per share over the next 12 months.
-
What Do Analysts Say About Sanara MedTech?
Analysts are divided on their view about Sanara MedTech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sanara MedTech is a Sell and believe this share price will drop from its current level to $44.00.
-
What Is Sanara MedTech's Price Target?
The price target for Sanara MedTech over the next 1-year time period is forecast to be $44.00 according to 0 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SMTI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sanara MedTech is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of SMTI?
You can purchase shares of Sanara MedTech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sanara MedTech shares.
-
What Is The Sanara MedTech Share Price Today?
Sanara MedTech was last trading at $35.00 per share. This represents the most recent stock quote for Sanara MedTech. Yesterday, Sanara MedTech closed at $34.11 per share.
-
How To Buy Sanara MedTech Stock Online?
In order to purchase Sanara MedTech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.05% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.62% over the past day.
